Aurigene introduces AI/ML assisted drug discovery platform
Aurigene.AI is an end-to-end solution for small molecule drug discovery
Aurigene.AI is an end-to-end solution for small molecule drug discovery
Reconfirms a relative bioavailability of 65 percent and significant savings when using DL-methionine
Application based on results from the TROPION-Breast01 Phase III trial
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
For the treatment of stenotic lesions of arteriovenous fistula in the haemodialysis management of chronic renal failure
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
The surgeons were able to remove the entire breast while preserving the nipple through tiny hidden incisions
The report underscores significant advancements in healthcare delivery, showcasing how GenAI facilitates improved diagnostic accuracy, operational efficiency and patient engagement
Oscotec has successfully completed phase 2 study in patients with chronic ITP last year
Subscribe To Our Newsletter & Stay Updated